August 11, 2009

BY ELECTRONIC FILING

Marlene H. Dortch Secretary Federal Communications Commission 445 12th Street, SW Washington, D.C. 20554

Spectrum for the Medical Device Radiocommunication Service in the 413-457 MHz Band (ET Dkt. No. 09-36; RM-11404)

Amendment of Parts 2 and 95 of the Commission's Rules to Provide Additional

Dear Ms. Dortch:

Re:

I am submitting these comments to urge the Commission to adopt rules permitting the operation of medical micro-power network ("MMN") devices in the 413-457 MHz band.

As a neurosurgeon, I perform many implantations per year of neural interface devices for Parkinson's disease, essential tremor, and axial or limb pain. Future devices will also provide significant benefit to patients who have psychiatric disorders. The ability to modulate the electrical output of these devices will significantly affect patient benefit.

I am familiar with the MMN devices that the Alfred Mann Foundation is developing, and I believe that these devices, if allowed to operate, will provide invaluable health benefits to millions of people suffering from neurodegenerative diseases, psychiatric diseases and other debilitating conditions. Specifically, these MMN devices are designed to operate as an artificial nervous system to restore sensation, mobility, and other functions to paralyzed and paretic limbs and organs. They can be used to treat a broad range of injuries and conditions, including severe spinal cord and brain injuries, debilitating disorders such as cerebral palsy and osteoporosis, and more common afflictions such as arthritis and headache.

Unlike any other medical treatment option available today, MMN devices offer a novel wireless solution that addresses the significant limitations in the previously available technologies. They provide a safer, less invasive, more convenient, and more effective treatment option than existing alternatives.

Because the benefits offered by MMN devices are immeasurable and cannot be replicated by other existing technologies, I urge the Commission to act expeditiously to adopt the rules necessary to foster the development of this extraordinary technology.

Sincerely,

Mark A Liker, MD, CFA, FACS

Assistant Professor, Department of Neurosurgery USC Keck School of Medicine

7